Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States.
Info & Links
CEO
Han Ying
Headquarters
12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO, CA 92130, UNITED STATES
Grant Thornton Zhitong Certified Public Accountants LLP
Share holders
44
Employees
579
Gyre Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
672.57M
Enterprise Value
636.08M
Enterprise Value/EBITDA(ttm)
55.49
Price to Earnings Ratio(ttm)
155.00
Price to Sales(ttm)
7.30
Price to Book(mrq)
5.61
Price to Cash(ytd)
39.24
Profitability
Gross Margin(ttm)
95.92%
Operating Margin(ttm)
8.08%
Profit Margin(ttm)
4.48%
Return on Equity(ttm)
7.67%
Return on Invested Capital(ttm)
8.28%
Return on Assets(ttm)
6.19%
Income Statement
Revenue(ttm)
102.19M
Revenue Per Share(ttm)
1.06
Gross Profit(ttm)
98.01M
EBITDA(ttm)3
11.46M
Net Income Available to Common(ttm)
4.17M
Diluted EPS(ttm)
0.01
Share Statistics
Beta (5Y Monthly)
1.88
52-Week Change
-48.83%
S&P 500 52-Week Change
19.69%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
96.31M
Dividend Yield
0.00%
Float4
86.68M
% Held by Insiders
10.00%
% Held by Institutions
23.99%
Balance Sheet
Total Cash(mrq)
54.37M
Total Cash Per Share(mrq)
0.56
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
5.40%
Quick Ratio(mrq)
4.87%
Book Value Per Share(mrq)
1.43
Cash Flow
Operating Cash Flow Per Share(ytd)
0.02
Free Cash Flow(ytd)
1.60M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.